Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beyond Air Inc XAIR

Healthcare Medical Devices
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for... see more

Recent & Breaking News (NDAQ:XAIR)

AIT Therapeutics Announces Third Quarter Financial Results Conference Call/Webcast

GlobeNewswire October 24, 2017

AIT Therapeutics Announces the Last Patient Has Completed Dosing in its Phase 2 NO-NTM Clinical Trial for Patients Suffering from Nontuberculous Mycobacteria (NTM) Abscessus

GlobeNewswire October 23, 2017

AIT Therapeutics’ Inhaled Nitric Oxide Therapy Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Treating Infections Caused by Nontuberculous Mycobacteria (NTM)

GlobeNewswire October 3, 2017

AIT Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference

GlobeNewswire September 20, 2017

AIT Therapeutics’ Adjuvant Nitric Oxide Treatment Shown to be Safe and Effective in the Compassionate Use Setting in Cystic Fibrosis Patients with Non-tuberculous Mycobacteria (NTM) Infection

GlobeNewswire September 13, 2017

AIT Therapeutics Reports Second Quarter 2017 Financial Results

GlobeNewswire August 11, 2017

AIT Therapeutics Announces Enrollment of First Patient into Its NO-NTM abscessus Phase 2 Trial in Nontuberculous Mycobacteria (NTM)

GlobeNewswire August 7, 2017

AIT Therapeutics to Report Second Quarter Financial Results on Friday, August 11

GlobeNewswire July 27, 2017

AIT Therapeutics to Participate in the JMP Securities Life Science Conference

GlobeNewswire June 15, 2017

AIT Therapeutics Announces Appointment of Steve Lisi as Chief Executive Officer

GlobeNewswire June 14, 2017

AIT Therapeutics Inc. Raises Gross Proceeds of $10.9 Million and Completes Reverse Merger

GlobeNewswire April 4, 2017